Nexalin Technology CEO Provides Letter to Shareholders
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology, under CEO Mark White, has reported significant progress in 2023 and is poised for greater achievements in 2024, focusing on improving mental healthcare outcomes. The company announced positive clinical results for its Gen-2 tACS device in treating mTBI and PTSD among military veterans, and chronic insomnia in adults, with data published in the Journal of Psychiatric Research. Nexalin introduced the HALO™ Clarity and the Virtual Clinic, aiming to enhance treatment accessibility. The company has formed a military and government advisory board, received regulatory approval in Oman, and is pursuing FDA approval in the US. Nexalin's IP portfolio has been strengthened with new patents extending through 2040, covering its core technology and the HALO™ Clarity system.
April 10, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology has reported significant advancements in mental health treatment, including positive clinical results, introduction of new technology, and global expansion efforts.
The positive clinical results and introduction of innovative products like the HALO™ Clarity and Virtual Clinic are likely to enhance Nexalin's market position and investor confidence. Regulatory approvals and the formation of a military and government advisory board further support the company's growth trajectory. These developments, combined with the strengthening of the IP portfolio, position Nexalin for potential short-term stock appreciation.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100